Page 85 - GTM-3-4

Global Translational Medicine

ORIGINAL RESEARCH ARTICLE
Blood laboratory parameters can predict

relapse-free survival of patients with advanced
squamous cell lung cancer and adenocarcinoma

1
Anatoli D. Tahanovich * , Mikalai M. Kauhanka 1 , Alexander V. Kolb 1 ,
Oxana V. Gotko 2 , and Violetta I. Prokharova 2
1 Department of Biochemistry, Educational Institution “Belarusian State Medical University”, Minsk,
Belarus
2 Department of Laboratory Methods of Diagnostics, N.N. Alexandrov National Cancer Center of
Belarus, a.g. Lesnoy, Belarus

Abstract
The aim of the work was to study the relationship between the concentration of
cells and proteins in the blood of patients with Stage III squamous cell lung cancer
(SCLC) and adenocarcinoma (AC) before surgical treatment and the duration of the
relapse-free period after tumor resection to develop prognostic models for relapse-
free survival in these diseases. Using logistic regression equations, the models
incorporated variables included cytokeratin 19 fragment antigen 21-1 (CYFRA 21-1)
concentration, the proportion of lymphocytes expressing the C-X-C motif chemokine
receptor 1 (CXCR1), and monocytes expressing the C-X-C motif chemokine receptor
*Corresponding author: 2 for SCLC. For AC, the models included the CYFRA 21-1 concentration, lymphocytes
Anatoli D. Tahanovich] expressing the CXCR1 receptor, and the eosinophil-to-monocyte ratio. These models
(taganovich@bsmu.by)
can predict the probability of tumor recurrence based on measurements of blood
Citation: Tahanovich AD, parameters in the pre-operative period, with a prediction efficiency of 87.7% for
Kauhanka MM, Kolb AV, Gotko OV,
Prokharova VI. Blood laboratory SCLC and 89.0% for AC.
parameters can predict relapse-free
survival of patients with advanced
squamous cell lung cancer Keywords: Squamous cell lung cancer; Adenocarcinoma; Relapse; Prognosis;
and adenocarcinoma. Global CYFRA 21-1; CXCR1; CXCR2; Stage III
Transl Med. 2024:3(4):4865.
doi: 10.36922/gtm.4865
Received: September 16, 2024
Accepted: November 26, 2024
Published Online: December 13, 1. Introduction
2024
Lung cancer (LC) is one of the most common forms of malignant tumors. According
Copyright: © 2024 Author(s). to the histological structure, 80 – 85% of LC cases are classified as non-small cell LC
This is an Open-Access article (NSCLC). Within the NSCLC category, two main histological types are distinguished:
1
distributed under the terms of the
Creative Commons Attribution adenocarcinoma (AC) and squamous cell LC (SCLC). 2
License, permitting distribution,
and reproduction in any medium, In most patients, NSCLC is diagnosed at an advanced stage, often with disease
provided the original work is metastases present. About 30% of all NSCLC cases are patients with Stage III disease.
1,2
properly cited. According to the TNM classification, Stage III NSCLC is a heterogeneous group
3
Publisher’s Note: AccScience of tumors that differ in size, the presence of invasion into surrounding mediastinal
Publishing remains neutral with structures, and damage to the mediastinal lymph nodes. These are categorized as stage
regard to jurisdictional claims in
published maps and institutional IIIA (T1-2N2, T3N1, T4N0-1), Stage IIIB (T1-2N3, T3-4N2), and Stage IIIC (T3-4N3),
affiliations. each of which determines the particular treatment regimen. Surgical treatment is

Volume 3 Issue 4 (2024) 1 doi: 10.36922/gtm.4865